Related Experiment Video

Updated: Sep 2, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Immunotherapeutic targets in non-small cell lung cancer

Habib Sadeghirad1, Tayyeb Bahrami2, Sepideh M Layeghi3

  • 1University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Immunology
|August 7, 2022
PubMed

Insights

Immunotherapy shows promise for non-small cell lung cancer (NSCLC), but effectiveness varies. Understanding the tumour microenvironment (TME) is crucial for optimizing NSCLC treatment strategies and improving patient responses to immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Non-small cell lung cancer (NSCLC) has a low 5-year survival rate (~20%).
  • Immunotherapies offer durable responses but benefit only a subset of NSCLC patients.
  • The tumour microenvironment (TME) significantly influences cancer progression and treatment efficacy.

Purpose of the Study:

  • To review immunotherapeutic targets in NSCLC.
  • To explore the role of the TME in NSCLC immunotherapy response.
  • To guide therapeutic strategies through comprehensive TME profiling.

Main Methods:

  • Literature review of current research on NSCLC, TME, and immunotherapy.
  • Analysis of signalling pathways within the TME (stroma, immune, endothelial cells).
  • Discussion of TME's impact on patient response to immunotherapies.

Main Results:

  • The TME comprises a complex network of cells influencing tumour initiation, growth, and spread.
  • Cytotoxic and cytoprotective signalling pathways are generated by TME components.
  • TME characteristics are critical determinants of immunotherapy effectiveness in NSCLC.

Conclusions:

  • In-depth TME profiling is essential for selecting optimal NSCLC therapies.
  • Targeting the TME holds potential for enhancing immunotherapy outcomes in NSCLC.
  • Further research into TME-immunotherapy interactions is needed to improve patient survival rates.
Keywords:
NSCLCTMEimmunotherapynon-small cell lung cancertumour microenvironment

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.3K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
650
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K